The REF funds groundbreaking research resulting in better care and treatment for more than 50 million Americans affected by rheumatic diseases. As the largest private funding source of rheumatology research and training programs in the U.S., the REF has awarded over $50 million to more than 1,000 recipients in the past five years. As a result, rheumatologists and healthcare professionals gain the knowledge and resources to provide their patients with the best possible care.
Related Articles
An Overview of Pediatric, Noninfectious Uveitis
Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…
Watch Those Eyes
What you need to know about Uveitis in Rheumatic Diseases
The Type I Interferon Pathway’s Influence in Connective Tissue Disease
Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…
A Look Back & A Look Ahead: ACR Research and Education Foundation Turns 25
The ACR Research and Education Foundation turns 25